Aphakia

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

T. Hunter Newsom, MD Returns to His Hometown and Joins His Father, Dr. William Newsom of Eye Associates of Gainesville, Bringing Innovative Technologies to Alachua County

Retrieved on: 
Friday, December 15, 2023
ICL, Research, Keratoconus, Patient, University, Collagen, FDA, CXL, Aphakia, Cataract, Mayo Clinic, Lens, EVO, Health, LAL, Telescopic sight, Hunting, Dentistry, MD, LASIK, Ophthalmology

GAINESVILLE, Fla., Dec. 15, 2023 /PRNewswire-PRWeb/ -- T. Hunter Newsom, MD, a distinguished Tampa-based ophthalmologist and founder of Newsom Eye, has returned to his hometown of Gainesville, Florida, and is adding a new location, Eye Associates of Gainesville. Dr. T. Hunter Newsom brings a wealth of expertise in advanced eye care, including the pioneering Light Adjustable Lens and Collagen Cross-Linking (CXL) for keratoconus patients, and will be working alongside his father, William Newsom, MD.

Key Points: 
  • T. Hunter Newsom, MD, a board-certified ophthalmologist, specializes in cataract, LASIK surgery, and the EVO Implantable Contact Lens (ICL) procedures.
  • T. Hunter Newsom, MD, alongside his wife Stacy Newsom, both alumni of the University of Florida, cherish deep ties with the community.
  • Under T. Hunter Newsom MD's leadership, Newsom Eye has been at the forefront of ophthalmological advancements, participating in multiple FDA studies.
  • The collaboration between T. Hunter Newsom, MD and Eye Associates of Gainesville marks a new chapter in providing top-tier eye care in the region.

SIFI ANNOUNCES CERTIFICATION OF WELL FUSION® ACCORDING TO EU MDR

Retrieved on: 
Wednesday, September 6, 2023
Presbyopia, MDR, Aphakia, EU, Patient, MINI, WELL, EDOF, Medical device, Telescopic sight

CATANIA, Italy, Sept. 6, 2023 /PRNewswire/ -- SIFI, a leading international eye care company, announces that the MINI WELL and MINI WELL PROXA intraocular lenses, as well as their combined use, commercially known as WELL FUSION®, are now certified for cataract surgery and refractive lens exchange, according to the European Union medical device regulation 2017/745 (MDR).

Key Points: 
  • WELL FUSION® is the first and only binocular optical system based on wavefront aberrations to correct presbyopia after removal of the natural lens.
  • CATANIA, Italy, Sept. 6, 2023 /PRNewswire/ -- SIFI, a leading international eye care company, announces that the MINI WELL and MINI WELL PROXA intraocular lenses, as well as their combined use, commercially known as WELL FUSION®, are now certified for cataract surgery and refractive lens exchange, according to the European Union medical device regulation 2017/745 (MDR).
  • "We are pleased to reach such a regulatory milestone, ensuring patients will continue to have access to WELL FUSION® beyond the regulatory transition period in Europe."
  • stated Fabrizio Chines, SIFI Chairman and CEO "The clinical evidence generated since 2021 confirmed that our pioneering and patented technology effectively delivers uninterrupted high-quality vision at all distances after cataract surgery and refractive lens exchange, meeting the stricter requirements of the EU MDR."

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Retrieved on: 
Thursday, September 29, 2022
Medical Supplies, Biotechnology, Technology, Health, Optical, Robotics, Health Technology, Medical Devices, Surgery, Audio, Video, Hardware, Adult, ROI, American Academy, Contraindication, Aphakia, ARGOS, Lists of diseases, Patient, Physician, Irritation, Bleeding, Central Time, Glaucoma, Eye, User, SMS, Cornea, Student, Visual acuity, Approximation error, Direction, Glasses, Surgeon, American Academy of Ophthalmology, Virtual reality, NYSE, Risk, ORA, News, Diabetes, Presbyopia, Region, Disorder, Light, AAO, SS, Eyelid, Incidence, Intraocular lens, Fidelis, Astigmatism, Retina, Maintenance, Patient satisfaction, Cataract, Life: A User's Manual, Quality of life, Use, Solution, Family, Red, Vision system, Iris, Swelling, Miyata, Telescopic sight, Medical imaging, Dentistry, Medicine, Alcon, IOL, Ophthalmology

Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.

Key Points: 
  • Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.
  • These activities will take place at Alcon booth #3926 at the AAO exhibit hall, on Oct. 1-3 from 9:00 a.m.5:00 p.m. Central Time.
  • The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.

Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology

Retrieved on: 
Wednesday, September 28, 2022
Storm, Adult, American Academy, Lens, Aphakia, Cataract, American Academy of Ophthalmology, Lists of diseases, Ophthalmology, Patient, Clinical trial, U.S. Securities and Exchange Commission, Exercise, Technology, Perception, Muscular dystrophy, Biostatistics, Risk, Temperature, EDOF, Amblyopia, Annual general meeting, Life, Rotation, GLARE, Cerebral edema, Johnson & Johnson, Visual acuity, Annual report, Direction, Doctor of Philosophy, Surgeon, Behavior, Color, MD, Emmetropia, Language interpretation, Medtech, IOL, Presbyopia, Severe cognitive impairment, EMEA, Security (finance), Light, Endophthalmitis, Health, AAO, Vision, LinkedIn, Johnson & Johnson Vision, Astigmatism, Private Securities Litigation Reform Act, Eye, Use, Diagnosis, Fine chemical, Telescopic sight, Pharmaceutical industry, Facebook

IRVINE, Calif., Sept. 28, 2022 /PRNewswire/ -- Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight, TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light performance across the PC-IOL category.1,2,3 The InteliLight portfolio will be on display at the 2022 American Academy of Ophthalmology's Annual Meeting (AAO) in Chicago, Sept. 30-Oct. 3.

Key Points: 
  • To learn more about the InteliLight portfolio, please visit https://www.jnjvisionpro.com/intelilight in the U.S.
    At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide.
  • Visit us at jjvision.com , follow @JNJVision on Twitter , Johnson & Johnson Vision on LinkedIn , and @JNJVision on Facebook .
  • Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
  • **Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Retrieved on: 
Monday, September 26, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Optical, Adult, American Academy, Ocular hypertension, UBE, Health, Safety, Lens (anatomy), IOP, Risk, MD, FDA, Food, Prevalence, Glaucoma, Macular edema, Aphakia, CME, World Health Organization, Senior, Inc., Drainage, Achievement, Timolol, Severe cognitive impairment, EP2, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, OTC, API, Quigley, Uncertainty, Humour, General manager, Diagnosis, Research, Optic nerve, American Academy of Ophthalmology, Drug discovery, Disease, Field line, Pharmaceutical industry, House of Santen, Ophthalmology, QD

OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.

Key Points: 
  • OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.
  • We are very pleased that this ophthalmic solution has been approved for glaucoma in the U.S., following approvals in Japan and Asia.
  • We have high expectations that omidenepag isopropyl will provide a new treatment option for more patients suffering from glaucoma and ocular hypertension through Santen.
  • OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S.

Retrieved on: 
Monday, March 7, 2022
Health, Medical Devices, Surgery, Other Health, General Health, Pharmaceutical, Optical, Aphakia, Population, S, DOI, Direction, Use, Radiation, Comparison, Physician, Ageing, PMID, Mark (given name), Family, Adult, Cataract, Quality of life, Astigmatism, Glasses, National Institute for Health and Care Excellence, Ophthalmology, Incidence, Trial of the century, Steroid, Eye, Approximation error, Flaxman, NYSE, CA, Haze, Safety, Snellen, Patient, Severe cognitive impairment, Innovation, Systematic review, Rotation, Katherine Clerk Maxwell, Intraocular lens, Retina, Refraction, Presbyopia, GLARE, Meta-analysis, Diabetes, Glaucoma, Telescopic sight, Medical device, Veterinary medicine, Medicine, Personal protective equipment, Fused quartz, Alcon, MD, IOL

At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients, said Ian Bell, President, Global Business & Innovation, Alcon.

Key Points: 
  • At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients, said Ian Bell, President, Global Business & Innovation, Alcon.
  • Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023.
  • More than 92% of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.21
    The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.